Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Reactions02:06

Allergic Reactions

Overview
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
Cross-reactivity00:42

Cross-reactivity

Overview
Hypersensitivities01:30

Hypersensitivities

Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Major Allergen Content in Allergen Immunotherapy Products: The Limited Value of Numbers.

Journal of investigational allergology & clinical immunology·2022
Same author

European survey on national training activities in clinical research.

Trials·2019
Same author

Letter to the Editor: Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.

Journal of the European Academy of Dermatology and Venereology : JEADV·2018
Same author

Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project.

Clinical and translational allergy·2016
Same author

Allergen-specific immunotherapy: is it vaccination against toxins after all?

Allergy·2016
Same author

IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT-Feld1 in human.

Allergy·2016

Related Experiment Video

Updated: Jun 7, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

[Allergen specific immunotherapy: new approaches].

F Tay1, T M Kündig, G Senti

  • 1Clinical Trials Center, Zentrum für Klinische Forschung, Universitätsspital und Universität Zürich, Zürich. fabian.tay@usz.ch

Praxis
|October 21, 2010
PubMed
Summary

Specific immunotherapy (SIT), a 100-year-old treatment for IgE-mediated allergies, is being improved. New methods like epicutaneous immunotherapy (a skin patch) are being tested for better safety and effectiveness.

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Related Experiment Videos

Last Updated: Jun 7, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Area of Science:

  • Allergy and Immunology
  • Dermatology
  • Pharmacology

Background:

  • Specific immunotherapy (SIT) is the sole causal and disease-modifying treatment for IgE-mediated allergic diseases.
  • Subcutaneous immunotherapy (SCIT) is the established gold standard for SIT.
  • There is a continuous need to enhance the efficacy, safety, and patient experience of allergy treatments.

Purpose of the Study:

  • To investigate novel strategies for SIT to improve upon current standards.
  • To evaluate the potential of epicutaneous immunotherapy (EPIT) as a safer and more desirable alternative.
  • To assess the clinical efficacy and safety of EPIT in ongoing trials.

Main Methods:

  • Investigating epicutaneous immunotherapy (EPIT) as a novel SIT approach.
  • Administering allergens via a skin patch for transdermal delivery.
  • Conducting clinical trials at Zurich University Hospital to evaluate EPIT.

Main Results:

  • EPIT is under active investigation as a potential advancement in SIT.
  • The use of a skin patch aims to enhance treatment delivery and patient adherence.
  • Early findings from clinical trials are anticipated to guide future therapeutic development.

Conclusions:

  • EPIT represents a promising evolution in the long-standing field of SIT.
  • The development of EPIT seeks to address limitations of traditional SCIT.
  • Further clinical research will determine the role of EPIT in managing allergic diseases.